18:08 IST
BSE
Earnings Call
Concord Biotech Earnings Call Transcript: Key Takeaways
Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.
Concord Biotech Ltd
- Share price
- ₹1,453.60
- Market cap
- ₹15,207 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 55.2×Sector 50.4×
- Promoter holding
- 44.08%+0.00% QoQ
- FII holding
- 7.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
18:52 IST
BSE
Earnings Call
Concord Biotech Investor Presentation: Key Takeaways
Concord Biotech reported strong Q1FY27 consolidated performance with 26% revenue growth and 31% PAT growth, driven by a 46% surge in exports and expanding market share in niche fermentation APIs.
18:35 IST
BSE
Earnings Call
Concord Biotech Earnings Call: Key Takeaways
Concord Biotech reported a challenging FY26 with a 12% revenue decline and 30% PAT drop due to geopolitical headwinds, tender delays, and regulatory holdups. Management remains optimistic for a stronger FY27.
18:07 IST
BSE
Earnings Call
Concord Biotech Earnings Call: Key Takeaways
FY26 was a rough year marked by geopolitical disruptions and US procurement slowdowns. Management pivots to a recovery narrative for FY27, banking on new injectable facilities and US direct marketing to reverse recent de-growth.
13:44 IST
BSE
Earnings Call
Concord Biotech Earnings Call: Key Takeaways
Concord Biotech reported a challenging FY26 with consolidated revenue at ₹1,054.9 Cr (-12% YoY) and PAT at ₹259.2 Cr (-30% YoY) due to procurement delays and geopolitical issues.